Skip to content

Non-randomised trial, 1983

Can promegestone treat premenstrual syndrome?

Possibly, but this study did not test it for PMS. The study tested promegestone for luteal insufficiency and found it more potent than dydrogesterone. The authors suggest it may help with PMS, but only based on its properties, not actual testing.

Early or limited evidence Not specified in abstract

What they did

A double-blind clinical trial tested promegestone (0.125 mg or 0.250 mg) against dydrogesterone (10 or 20 mg) for luteal insufficiency. The authors also discuss its potential use for hormone-dependent breast cancer and psychological symptoms of PMS and perimenopause.

What they found

Promegestone showed significantly superior potency compared to dydrogesterone (p less than 0.001). The authors propose it may be useful for treating hormone-dependent breast cancer and the psychological disorders of PMS and perimenopause.

What it means for you

Promegestone may be a more potent progestin than existing options, possibly including for PMS, but this study did not actually test it for PMS. This is from 1983 and presented as preliminary speculation. Newer research may provide clearer answers.

0.125-0.250 mg

Promegestone dose tested

p < 0.001

Significantly more potent than dydrogesterone

About the study

Original title
[Promegestone, a new progestin]
Authors
Raynaud JP, Ojasoo T
Journal
Journal de gynecologie, obstetrique et biologie de la reproduction
Year
1983
Study design
Non-randomised trial
What was tested
Promegestone 0.125-0.250 mg vs dydrogesterone 10-20 mg for luteal insufficiency

Topics